E. Guggenberg

[99mTc]HYNIC-RGD for imaging integrin αvβ3 expression

C. Decristoforo, R. Haubner, M. Rupprich, 2006 .

Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions.

E. Guggenberg, M. Klingler, A. A. Hörmann, 2020, Current medicinal chemistry.

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177

R. Gust, S. Shahhosseini, E. Guggenberg, 2020, Molecules.

Methoxinine – an alternative stable amino acid substitute for oxidation‐sensitive methionine in radiolabelled peptide conjugates

R. Schibli, M. Béhé, T. Mindt, 2017, Journal of peptide science : an official publication of the European Peptide Society.

Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607

M. Jong, W. Breeman, J. Reubi, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans

R. Moncayo, E. Donnemiller, C. Decristoforo, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression

B. Pichler, C. Decristoforo, I. Virgolini, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.

C. Decristoforo, R. Mikołajczak, E. Guggenberg, 2004, Journal of pharmaceutical sciences.

99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours

C. Decristoforo, I. Virgolini, E. Guggenberg, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Preparation via coligand exchange and characterization of [99mTc‐EDDA‐HYNIC‐D‐Phe1,Tyr3]Octreotide (99mTc–EDDA/HYNIC–TOC)

B. Sarg, H. Lindner, R. Moncayo, 2003 .

Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation

C. Kremser, B. Keppler, W. Jaschke, 2010, Histochemistry and Cell Biology.

Abstracts from the 20th European symposium on radiopharmacy and radiopharmaceuticals

G. Bormans, Y. Seimbille, O. Fedorova, 2023, EJNMMI Radiopharmacy and Chemistry.

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide

G. Widmann, C. Decristoforo, I. Virgolini, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging

C. Decristoforo, M. Béhé, C. Rangger, 2009 .

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer

I. Virgolini, C. Uprimny, B. Warwitz, 2023, The Journal of Nuclear Medicine.

Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

R. Bale, C. Decristoforo, I. Virgolini, 2007 .

99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.

R. Moncayo, C. Decristoforo, I. Virgolini, 2005, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....